DIRS.INFO The most relevant business & tech news

Scientists are keeping an eye on the new lineage, named BA.2.86, because it has 36 mutations that distinguish it from the currently-dominant XBB.1.5 variant. So far there is no evidence that BA.2.86 spreads faster or causes more serious illness than previous versions. COVID infections and hospitalizations have been rising in the U.S., Europe and Asia, with more cases in recent months attributed to the EG.5 "Eris" subvariant, a descendant of the Omicron lineage that originally emerged in November 2021. But many countries have drastically reduced testing of patients and their efforts to analyze the genomes of the viruses causing new COVID cases. Updated COVID booster shots now being developed have been designed to target the Omicron subvariant XBB.1.5.

Persons: Emily Elconin, Wesley Long, Eric Topol, Topol, Long, Moderna, Eris, Deena Beasley, Nancy Lapid, David Gregorio Our Organizations: REUTERS, Moderna Inc, Pfizer, World Health Organization, U.S . Centers for Disease Control, CDC, EG, Omicron, Houston Methodist Hospital, Scripps Research, COVID, U.S, Pfizer Inc, Thomson Locations: Waterford , Michigan, U.S, Europe, Asia, United States, Israel, Denmark, La Jolla , California

☆ New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant
▼ + stars: | 2023-08-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

New Covid vaccines from Pfizer , Moderna and Novavax will likely provide protection against the new "Eris" variant, now the dominant strain of the virus in the U.S. The drugmakers designed their updated vaccines to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. Eris accounted for 17.3% of all cases in the U.S. as of earlier this month, according to the latest data from the CDC. The World Health Organization earlier this month designated Eris a "variant of interest," meaning it will be monitored for mutations that could potentially make it more severe. It's also not expected to cause a huge wave of Covid cases like other strains have in previous years.

Persons: Dr, Mark Mulligan, It's Organizations: Chicago Department of Public Health, Southwest Senior Center, Pfizer, Moderna, U.S, EG, NYU, Vaccine, CNBC, Food and Drug Administration, Disease Control, CDC, World Health Organization Locations: Covid, Chicago , Illinois, Novavax, U.S

☆ Moderna says new Covid vaccine was effective against Eris variant in early trial
▼ + stars: | 2023-08-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Moderna's new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday. The updated shot is designed to target omicron subvariant XBB.1.5, but the results suggest that the jab may still be effective against newer variants of the virus that are gaining ground nationwide. That includes Eris and another variant nicknamed Fornax, both of which are also descendants of the omicron virus variant. The World Health Organization designated Eris a "variant of interest," meaning it will be monitored for mutations that could make it more severe. A Pfizer spokesperson on Thursday said the company's own updated Covid shot effectively neutralized XBB.1.5 and Eris, among other variants, in a recent trial on mice.

Persons: Eris Organizations: omicron, Pfizer, Novavax, U.S . Food, Drug Administration, EG, Centers for Disease Control, World Health Organization, CDC Locations: U.S

☆ Moderna's updated COVID vaccine effective against 'Eris' variant in humans
▼ + stars: | 2023-08-17 | by ( ) www.reuters.com time to read: +2 min

Vials of the Moderna COVID-19 vaccine are seen at Apotex pharmaceutical company as Humber River Hospital's mobile vaccine clinic vaccinate employees as part of the coronavirus disease (COVID-19) vaccination campaign, in Toronto, Ontario, Canada April 13, 2021. REUTERS/Carlos Osorio/File Photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesAug 17 (Reuters) - Moderna (MRNA.O) said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other COVID-19 vaccine makers Novavax (NVAX.O), Pfizer (PFE.N) and German partner BioNTech SE (22UAy.DE) have created versions of their shots aimed at the XBB.1.5 subvariant. Earlier on Thursday, Pfizer reported that its updated COVID-19 shot, co-developed with BioNTech, showed neutralizing activity against the Eris subvariant in a study conducted on mice. Eris, the nickname for EG.5, is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant.

Persons: Carlos Osorio, BioNTech, Pratik Jain, Shilpi Majumdar Organizations: Moderna, REUTERS, Pfizer, EG, Omicron, World Health Organization, Thomson Locations: Humber, Toronto , Ontario, Canada, United States, Europe, U.S, Bengaluru

☆ Pfizer's updated COVID shot effective against 'Eris' variant in mice study
▼ + stars: | 2023-08-17 | by ( ) www.reuters.com time to read: +1 min

Pfizer, along with its German partner BioNTech SE (22UAy.DE), as well as other COVID-19 vaccine makers Moderna (MRNA.O) and Novavax (NVAX.O) have created versions of their shots, which are aimed at the XBB.1.5 subvariant. EG.5, nicknamed by some as "Eris", is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant. EG.5 accounted for about more than 17% of COVID-19 cases in the United States, according to the latest government data. In the United States, COVID-19 related hospitalizations are up more than 40% off of recent lows hit in June, but are still more than 90% below peak levels hit during the January 2022 Omicron outbreak. Reporting by Pratik Jain in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Chris Aluka Berry, BioNTech, Pratik Jain, Shilpi Majumdar Organizations: Dekalb Pediatric Center, REUTERS, Pfizer, Pfizer Inc, Moderna, EG, World Health Organization, Thomson Locations: Dekalb, Georgia, Decatur , Georgia, U.S, United States, China, South Korea, Japan, Canada, Bengaluru

☆ Dr. Scott Gottlieb: Nothing suggests new 'Eris' Covid variant is more pathogenic than prior variants
▼ + stars: | 2023-08-16 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Scott Gottlieb: Nothing suggests new 'Eris' Covid variant is more pathogenic than prior variantsFormer FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the new 'Eris' Covid variant after the World Health Organization called it a 'variant of interest', how concerned should the public be, whether new vaccines are in the works, and more.

Persons: Scott Gottlieb Organizations: FDA, World Health Organization

☆ The next Covid booster is on the horizon: Will the vaccine be covered by insurance?
▼ + stars: | 2023-08-16 | by ( Renée Onque | ) www.cnbc.com time to read: +3 min

Now that the national emergency is no longer in effect, many are wondering if their insurance will cover the latest booster shots. Will insurance cover the newest Covid booster? If you get your vaccines at your local pharmacy, consider asking a pharmacist at the location if your insurance covers Covid boosters, she adds. If you don't have insurance or your provider isn't covering the cost of your vaccine, booster shots should also be available for free through local public health authorities, Patel adds. What else should you know about the 'Eris' Covid variant?

Persons: Payal Patel, Patel, Sorana Segal, Maurer, Segal, you'll, who've Organizations: EG, Intermountain Health, World Health Organization, CNBC, Presbyterian Queens Locations: Salt Lake City, U.S, NewYork, Covid

☆ As the new Eris Covid variant spreads across the world, here’s what we know so far
▼ + stars: | 2023-08-15 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

An illustrative image of a person holding a medical syringe and a vaccine vial in front of the Pfizer logo displayed on a screen. The World Health Organization is monitoring a new strain of Covid-19 called EG.5, or "Eris," that accounts for a growing share of cases in countries including China and the United States. The WHO has designated it a "variant of interest," meaning it will be monitored for mutations that could make it more severe. Based on current evidence, the WHO says it presents a low public health risk at a global level, in-line with other variants currently in circulation. It added that these properties may lead the variant to become dominant in some countries, or indeed globally.

Organizations: Pfizer, World Health Organization, WHO Locations: China, United States

☆ Covid Eris: What to know about new variant EG.5 dominating U.S. cases
▼ + stars: | 2023-08-14 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

NEW YORK, Aug 14 (Reuters) - COVID infections and hospitalizations are on the rise in the U.S., Europe and Asia. Health officials are pointing at the EG.5 "Eris" coronavirus, a subvariant of the Omicron lineage that originally emerged November of 2021. EG.5 had been found in more than 50 countries as of August 8, according to the WHO. It is the most common and fastest growing COVID-19 subvariant in the U.S., estimated to be responsible for around 17% of current COVID cases, according to the CDC. EG.5 is similar to XBB.1.5 although the newer subvariant carries one mutation to its spike protein, the part of the virus targeted by the vaccine.

Persons: Mandy Cohen, Cohen, Michael Erman, Caroline Humer, Diane Craft Organizations: Health, EG, Omicron, World Health Organization, WHO, CDC, Pfizer, Thomson Locations: U.S, Europe, Asia

☆ New Covid vaccines are on the way as 'Eris' variant rises
▼ + stars: | 2023-08-14 | by ( Michael Erman | ) www.reuters.com time to read: +5 min

Some public health experts hope that Americans will welcome the new shot as they would a flu jab. In the fall of 2022, by which time most people had either had the COVID virus or the vaccine, fewer than 50 million people got the shots. Its biggest rival, Moderna, conceded demand could be as few as 50 million shots. POST PANDEMIC VACCINEThe COVID public health emergency ended in May and the government has handed much of the duty of vaccinating America to the private sector. As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.

Persons: Dado Ruvic, Ashley Kirzinger, Kirzinger, BioNTech, Jefferies, Michael Yee, " Yee, Mandy Cohen, William Schaffner, Schaffner, David Boulware, Michael Erman, Caroline Humer, Diane Craft Organizations: REUTERS, CVS Health, Family, Reuters, Pfizer –, Moderna, Pfizer, U.S . Centers for Disease Control, Prevention, CDC, U.S . Food, Drug Administration, EG, Vanderbilt University, University of Minnesota, Thomson Locations: U.S, America, United States, COVID, CDC's

☆ What to Know About the New Dominant Covid Variant
▼ + stars: | 2023-08-11 | by ( Dana G. Smith | More About Dana G. Smith | ) www.nytimes.com time to read: +1 min

The variant was identified in China in February 2023 and was first detected in the United States in April. It is a descendant of the Omicron variant XBB.1.9.2 and has one notable mutation that helps it to evade antibodies developed by the immune system in response to earlier variants and vaccines. That advantage may be why EG.5 has become the dominant strain worldwide, and it could be one reason Covid cases have started to rise again. Diagnostic tests and treatments such as Paxlovid continue to be effective against it, Dr. Pekosz said. “My main concern is for the people at high risk,” Dr. Topol said.

Persons: Pekosz, Eric Topol, Topol, ” Organizations: EG, Scripps Research Locations: China, United States, La Jolla, Calif

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/eg5-eris-new-covid-19-variant-fa3cc260

Persons: Dow Jones

☆ With Eris on the rise, US CDC sees no major shift in COVID variants
▼ + stars: | 2023-08-09 | by ( ) www.reuters.com time to read: +2 min

Updated vaccines should be available by mid- to late September, she said. The vaccines still need to be authorized by the U.S. Food and Drug Administration and the CDC needs to make its recommendations, she said. "We are likely to see this as a recommendation as an annual COVID shot just like we have an annual flu shot," she said. Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O) have all said they expect to have supplies of the updated vaccine ready for the roll out this autumn. Eris is the fasting-growing COVID-19 subvariant in the U.S., estimated to be responsible for around 17% of current COVID cases, according to the CDC.

Persons: Mandy Cohen, Biden, Andy Slavitt's, we've, Cohen, Michael Erman, Lisa Shumaker Organizations: EG, U.S . Centers for Disease Control, U.S . Food, Drug Administration, Pfizer, World Health Organization, CDC, Thomson Locations: United States, China, U.S, New York

☆ Analysis: Forex derivatives nudged out into the open as regulations increase costs
▼ + stars: | 2023-06-20 | by ( Laura Matthews | ) www.reuters.com time to read: +6 min

REUTERS/Dado Ruvic/IllustrationNEW YORK, June 20 (Reuters) - Foreign-exchange investors are moving more of their over-the-counter (OTC) derivatives trades to lookalike products on exchanges to avoid higher costs due to recent global regulations, helping inject transparency into a multitrillion-dollar market that is largely hidden from the public eye. The gradual behavioral change in FX derivatives trading is being caused by increasing margin and collateral costs, said Joe Midmore, chief commercial officer at OpenGamma, a derivatives analytics firm. OTC derivatives are privately negotiated contracts while cleared derivatives, though bilaterally negotiated, are booked with a clearinghouse such as a listed exchange. "They will also incur the operational, legal and custody costs of setting up margin facilities as well as the capital costs of posting margin," Houston said. "There is inherently risk involved in lots of people transacting derivatives with each other," said Riddle.

Persons: Dado Ruvic, Ben Feuer, Joe Midmore, ”, Michael Riddle, Paul Houston, Houston, ForexClear, James Pearson, Tom Arnold, Joe Spiro, Peter Vassallo, Riddle, Laura Matthews, Shankar Ramakrishnan, Megan Davies, Matthew Lewis Organizations: REUTERS, Societe Generale, Banking Supervision, International Organization of Securities Commissions, CME, CME Group, FX, Reuters Graphics British, Financial, ForexClear, BNP, Management, Thomson Locations: Saudi, New York, Hazeltree

Now, over the past two months, videos showing Borzois, and inanimate objects that look like them, have taken over TikTok. Jacob Chattman, a longtime Borzoi owner and content creator, said Borzois "embody the existential crisis of being way too aware of everything." Sad Borzois, Kambourian said, have recontextualized “Cellophane,” a devastating song in its original form, for many people. Like Chattman, Kelly said many sighthounds have a “magical” quality to them. “They just have such a different personality than other dogs,” Kelly said.

☆ India's Eris Lifesciences to buy some dermatology brands from Glenmark Pharma
▼ + stars: | 2023-01-17 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, Jan 17 (Reuters) - Indian drugmaker Eris Lifesciences Ltd (ERIS.NS) said on Tuesday it would acquire a portfolio of dermatology brands from Glenmark Pharmaceuticals Ltd (GLEN.NS) for 3.4 billion rupees ($41.63 million) to deepen its presence in the anti-fungal and anti-psoriasis segments. The deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for India and Nepal, Eris said. Glenmark said, post divestiture of the brands, it will further consolidate its position in the core therapeutic areas of cardiometabolic, respiratory, dermatology, and oncology segments. Separately, Eris on Tuesday reported a consolidated net profit of 1.02 billion rupees in its third quarter, from 1.01 billion rupees a year earlier. ($1 = 81.6740 Indian rupees)Reporting by Yagnoseni Das in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "eris"

16 mentions found